Fibrils Colocalize Caspase-3 with Procaspase-3 to Foster Maturation

From the Departments of Pharmaceutical Chemistry and.
Journal of Biological Chemistry (Impact Factor: 4.57). 08/2012; 287(40):33781-95. DOI: 10.1074/jbc.M112.386128
Source: PubMed


Most proteases are expressed as inactive precursors, or zymogens, that become activated by limited proteolysis. We previously
identified a small molecule, termed 1541, that dramatically promotes the maturation of the zymogen, procaspase-3, to its mature
form, caspase-3. Surprisingly, compound 1541 self-assembles into nanofibrils, and localization of procaspase-3 to the fibrils
promotes activation. Here, we interrogate the biochemical mechanism of procaspase-3 activation on 1541 fibrils in addition
to proteogenic amyloid-β(1–40) fibrils. In contrast to previous reports, we find no evidence that procaspase-3 alone is capable
of self-activation, consistent with its fate-determining role in executing apoptosis. In fact, mature caspase-3 is >107-fold more active than procaspase-3, making this proenzyme a remarkably inactive zymogen. However, we also show that fibril-induced
colocalization of trace amounts of caspase-3 or other initiator proteases with procaspase-3 dramatically stimulates maturation
of the proenzyme in vitro. Thus, similar to known cellular signaling complexes, these synthetic or natural fibrils can serve as platforms to concentrate
procaspase-3 for trans-activation by upstream proteases.

Download full-text


Available from: Nicholas Agard, Nov 25, 2015
  • Source
    • "2.6. Caspase activation assay [32] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Celastrol is an active compound extracted from the root bark of the traditional Chinese medicine Tripterygium wilfordii Hook F. To investigate the effect of celastrol on human multiple myeloma cell cycle arrest and apoptosis and explore its molecular mechanism of action. The activity of celastrol on LP-1 cell proliferation was detected by WST-8 assay. The celastrol-induced cell cycle arrest was analyzed by flow cytometry after propidium iodide staining. Nuclear translocation of the nuclear factor kappa B (NF-κB) was observed by fluorescence microscope. Celastrol inhibited cell proliferation of LP-1 myeloma cell in a dose-dependent manner with IC50 values of 0.8817 µM, which was mediated through G1 cell cycle arrest and p27 induction. Celastrol induced apoptosis in LP-1 and RPMI 8226 myeloma cells in a time and dose dependent manner, and it involved Caspase-3 activation and NF-κB pathway. Celastrol down-modulated antiapoptotic proteins including Bcl-2 and survivin expression. The expression of NF-κB and IKKa were decreased after celastrol treatment. Celastrol effectively blocked the nuclear translocation of the p65 subunit and induced human multiple myeloma cell cycle arrest and apoptosis by p27 upregulation and NF-kB modulation. It has been demonstrated that the effect of celastrol on NF-kB was HO-1-independent by using zinc protoporphyrin-9 (ZnPPIX), a selective heme oxygenase inhibitor. From the results, it could be inferred that celastrol may be used as a NF-kB inhibitor to inhibit myeloma cell proliferation.
    Full-text · Article · Apr 2014 · PLoS ONE
  • [Show abstract] [Hide abstract]
    ABSTRACT: Allostery is a fundamental regulatory mechanism which is based on a functional modulation of a site by a distant site. Allosteric regulation can be triggered by binding of diverse allosteric effectors, ranging from small molecules to macromolecules, and is therefore offering promising opportunities for functional modulation in a wide range of applications including the development of chemical probes or drug discovery. Here, we provide an overview of key classes of allosteric protease effectors, their corresponding molecular mechanisms and their practical implications.
    No preview · Article · Nov 2012 · ACS Chemical Biology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In the past 15 years, fragment-based lead discovery (FBLD) has been adopted widely throughout academia and industry. The approach entails discovering very small molecular fragments and growing, merging, or linking them to produce drug leads. Because the affinities of the initial fragments are often low, detection methods are pushed to their limits, leading to a variety of artifacts, false positives, and false negatives that too often go unrecognized. This Digest discusses some of these problems and offers suggestions to avoid them. Although the primary focus is on FBLD, many of the lessons also apply to more established approaches such as high-throughput screening.
    Full-text · Article · Mar 2013 · Bioorganic & medicinal chemistry letters
Show more